Progressive multifocal leukoencephalopathy during treatment with lenalidomide and elotuzumab for multiple myeloma

Leuk Lymphoma. 2020 Sep;61(9):2234-2237. doi: 10.1080/10428194.2020.1765237. Epub 2020 May 18.

Authors

Yuta Usui¹, Hiroto Nakano¹, Junji Komatsu¹, Kazuo Nakamichi², Masayuki Saijo², Seiichiro Takano³, Ken-Ichi Kamiya⁴, Tsuyoshi Hamaguchi¹, Masahito Yamada¹

Affiliations

¹ Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
² Department of Virology 1, National Institute of Infectious Diseases, Tokyo, Japan.
³ Department of Neurology, Fukui Red Cross Hospital, Fukui, Japan.
⁴ Department of Hematology, Fukui Red Cross Hospital, Fukui, Japan.

PMID: 32420767
DOI: 10.1080/10428194.2020.1765237

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Dexamethasone / therapeutic use
Humans
Lenalidomide / adverse effects
Leukoencephalopathy, Progressive Multifocal* / chemically induced
Leukoencephalopathy, Progressive Multifocal* / diagnosis
Multiple Myeloma* / drug therapy

Substances

Antibodies, Monoclonal, Humanized
elotuzumab
Dexamethasone
Lenalidomide